Progress on the Study of PD-L1 Detection Methods in Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2019.01.08
- Author:
Xuejing GUO
1
;
He CAO
1
;
Jianya ZHOU
1
;
Jianying ZHOU
1
Author Information
1. Department of Respiratory Disease, Thoracic Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310000, China.
- Publication Type:Journal Article
- Keywords:
Enzyme-linked immunosorbent assay;
Immunohistochemistry;
Non-small cell lung cancer;
PD-L1
- MeSH:
B7-H1 Antigen;
analysis;
Biomarkers, Tumor;
analysis;
Carcinoma, Non-Small-Cell Lung;
diagnosis;
metabolism;
Enzyme-Linked Immunosorbent Assay;
methods;
Humans;
Immunohistochemistry;
methods;
Lung Neoplasms;
diagnosis;
metabolism;
Reproducibility of Results;
Sensitivity and Specificity
- From:
Chinese Journal of Lung Cancer
2019;22(1):40-44
- CountryChina
- Language:Chinese
-
Abstract:
PD-1/PD-L1 inhibitors play an important role in the first-line and second-line treatment of non-small cell lung cancer (NSCLC), indicating a new treatment strategy of NSCLC. Completed clinical trials have shown that effective detection of PD-L1 expression is the key to the use of immunosuppressive agents. However, the gold standard for PD-L1 detection has still lacked. In recent years, immunohistochemistry (IHC) and enzyme-linked immunosorbent assay (ELISA) have been continuously innovated, which accounts for good prospect in PD-L1 detection. The research progress of PD-L1 detection methods in NSCLC is summarized in this review.
.
